Companies
Company news
Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.
2 articles on REGN
-
Regeneron Pharmaceuticals says Pasatru showed no new HO lesions in FOP
Late-breaking data presented at ASBMR show a consistent safety profile from weeks 56 to 84 of the OPTIMA trial extension.
-
In MRI substudy, trevogrumab prevented 70% of semaglutide-linked muscle loss
In a pre-specified subgroup meeting the low lean mass definition for sarcopenia, Regeneron Pharmaceuticals said semaglutide caused greater lean mass loss and trevogrumab more preservation.
How these are written
- The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
- The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
- The date: the day the company filed the 8-K or published the release.
- Not investment advice. An article reports what the company disclosed; it is not a view on the stock.
Follow companies on GetSignal
Their filings, insider trades and company news in one feed. Free on iPhone and Android.
